Ubs Group Ag Gamida Cell Ltd. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Gamida Cell Ltd. stock. As of the latest transaction made, Ubs Group Ag holds 201,000 shares of GMDA stock, worth $6,030. This represents 0.0% of its overall portfolio holdings.

Number of Shares

201,000

Holding current value

$6,030

% of portfolio

0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.04 - $0.46 $8,040 - $92,460	201,000 New	201,000 $8,000
Q2 2023 Aug 11, 2023	BUY	$0.73 - $2.37 $4,421 - $14,355	6,057 New	6,057 $11,000
Q4 2022 Feb 08, 2023	BUY	$1.15 - $2.1 $373 - $682	325 New	325 $0
Q2 2022 Aug 10, 2022	SELL	$1.73 - $4.29 $6,715 - $16,653	-3,882 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.22 - $4.47 $8,618 - $17,352	3,882 New	3,882 $16,000

Q4 2021 Feb 14, 2022	SELL	$2.2 - $4.46 $30,494 - $61,820	-13,861 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.85 - $6.44 $6,895 - $11,534	-1,791 Reduced 11.44%	13,861 $54,000
Q2 2021 Aug 13, 2021	BUY	$5.85 - $8.33 $29,758 - $42,374	5,087 Added 48.15%	15,652 $101,000
Q1 2021 May 12, 2021	BUY	$7.8 - $12.43 $44,101 - $70,279	5,654 Added 115.13%	10,565 $85,000
Q4 2020 Feb 11, 2021	SELL	$4.07 - $11.0 $50,797 - $137,291	-12,481 Reduced 71.76%	4,911 $41,000
Q3 2020 Nov 12, 2020	BUY	$3.93 - $4.59 $50,665 - $59,174	12,892 Added 286.49%	17,392 $73,000
Q1 2020 May 01, 2020	SELL	$2.9 - $4.76 $5,826 - $9,562	-2,009 Reduced 30.86%	4,500 $14,000
Q4 2019 Feb 14, 2020	BUY	$4.01 - $5.25 $26,101 - $34,172	6,509 New	6,509 $28,000
Q2 2019 Aug 14, 2019	SELL	$4.98 - $11.32 $60,073 - $136,553	-12,063 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$9.8 - $14.38 $100,577 - $147,581	10,263 Added 570.17%	12,063 $136,000
Q4 2018 Feb 14, 2019	BUY	$8.44 - $15.41 $15,192 - $27,738	1,800 New	1,800 $18,000

Others Institutions Holding GMDA

# of Institutions

Shares Held

11.4M

Call Options Held

235K

Put Options Held

70.5K

View Full List

About Gamida Cell Ltd.

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

More about GMDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account